Vor Biopharma Inc.
Vor Biopharma Inc. (Nasdaq: VOR) is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead and currently active product candidate, telitacicept, is a fusion protein that targets BAFF and APRIL, signaling molecules involved in B-cell development and autoimmune responses. Vor… From the company’s description.
In fiscal 2025, Vor Biopharma Inc. reported a net loss of $695.98M. Operations used $142.71M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vor Biopharma Inc. does
In the company’s own words
Vor Biopharma Inc. (Nasdaq: VOR) is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead and currently active product candidate, telitacicept, is a fusion protein that targets BAFF and APRIL, signaling molecules involved in B-cell development and autoimmune responses. Vor holds exclusive rights to develop and commercialize the product outside Greater China, while its licensor, RemeGen, retains rights in that region. Telitacicept is being evaluated in global Phase 3 trials for generalized myasthenia gravis and Sjögren’s disease; it is approved in China for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis. The company’s former programs focused on engineered stem-cell and cell therapies for blood cancers, but it wound down those operations in 2025 and sold certain related intellectual property. Vor has no commercial organization or distribution capabilities and relies on third parties for clinical manufacturing. Its business is focused on autoimmune therapeutics, with telitacicept as its lead candidate.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1817229
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vor Biopharma Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vor Biopharma Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vor Biopharma Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vor Biopharma Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vor Biopharma Inc.'s last four quarterly filings that the numbers alone won't show?”